In conclusion, the interaction between AURKA and the EGFR-L858R mutant may explain the difference in signaling pathways between EGFR-WT and mutant cells, which are frequently observed in NSCLC patients, and may thus provide valuable information for therapeutic applications. Here, AURKA is linked to non-small cell lung carcinoma.